Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Nuvalent, Inc.NASDAQ: NUVL
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $119.41M rose 25.9% year over year, behind the +36.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 16.8% from the prior quarter. Over 3 fiscal years it compounded at +68.8% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +25.9% toward the trailing-twelve-month pace of +36.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 414.31M USD
- Year-over-year change
- +47.8%
- 4-year CAGR
- +73.4%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 414.31M | +47.8% |
| FY2024 | 2024-12-31 | 280.37M | +87.5% |
| FY2023 | 2023-12-31 | 149.49M | +73.6% |
| FY2022 | 2022-12-31 | 86.11M | +87.9% |
| FY2021 | 2021-12-31 | 45.82M | — |
Operating Expenses vs competitors
How NUVL compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +36.1% is the 4th highest of 9, against a peer median of +30.5%.
- Over three fiscal years its annual growth of +68.8% compares with a peer median of +44.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.31B USD | -18.1% | +3.6% | 70.2% | |
| LTM Jun 2026 | $1.16B USD | +65.4% | +58.4% | — | |
| LTM Sep 2026 | $1.16B USD | +58.1% | +38.7% | 256.5% | |
| LTM Jun 2026 | $912.58M USD | +33.9% | +50.1% | 117.5% | |
| LTM Jun 2026 | $767.6M USD | +21.3% | +57.1% | 1081.7% | |
| LTM Mar 2026 | $438.9M USD | +36.1% | +68.8% | — | |
| LTM Sep 2026 | $434.94M USD | +27.2% | +21.8% | 154.9% | |
| LTM Sep 2026 | $389.17M USD | +13.2% | -15.6% | 1546.0% | |
| FY2025 | €246.06M EUR | +42.2% | +159.6% | — | |
| Peer median (excluding NUVL) | — | +30.5% | +44.4% | 205.7% | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.56M | 63.73M | 113.24M | 217.77M | 306.97M |
| Selling, General & Admin | 10.26M | 22.38M | 36.25M | 62.59M | 107.34M |
| Operating Expenses | 45.82M | 86.11M | 149.49M | 280.37M | 414.31M |
| Depreciation & Amortization | 215K | 0 | 0 | 280.37M | 414.31M |
| EBITDA | (46.12M) | (81.85M) | (126.22M) | 20.38M | (10.49M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (45.82M) | (86.11M) | (149.49M) | (280.37M) | (414.31M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 23.27M | 38.32M | 44.74M |
| Interest Expense | 0 | 0 | 23.27M | 0 | 0 |
| Other Income / Expenses | (521K) | 4.25M | 23.27M | 20.38M | (10.49M) |
| Income Before Tax | (46.34M) | (81.85M) | (126.22M) | (259.99M) | (424.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 764K | 585K |
| Net Income | (46.34M) | (81.85M) | (126.22M) | (260.76M) | (425.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.13) | (1.65) | (2.17) | (3.93) | (5.85) |
| EPS (Diluted) | (2.13) | (1.65) | (2.17) | (3.93) | (5.85) |
| Weighted Avg Shares | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M |
| Weighted Avg Shares (Diluted) | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.